Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug.
Passamonti
Francesco
F
Cazzola
Mario
M
D000328:Adult; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D010885:Pipobroman / Q000009:adverse effects / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011379:Prognosis; D012307:Risk Factors; D013920:Thrombocythemia, Essential / Q000150:complications / Q000188:drug therapy*; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*
D010975:Platelet Aggregation Inhibitors; D010885:Pipobroman; D006918:Hydroxyurea